2seventy bio-partnered Abecma (idecabtagene vicleucel) is already approved as a fourth-line or later therapy for the blood cancer, and the KarMMa-3 study is designed to support second or third ...

Bristol Myers Squibb (BMS) plans to buy out its partner in developing the blockbuster multiple myeloma drug Abecma ® (idecabtagene vicleucel), by agreeing to acquire 2seventy bio for ...

Abecma’s review was delayed after the FDA rejected a first filing in May last year, but it’s hoped that the drug could be a significant step forward in the treatment of this incurable condition.

Abecma (idecabtagene vicleucel) is a brand-name infusion prescribed for multiple myeloma in certain adults. Abecma is not known to interact with other medications or supplements. But it can ...

2seventy bio investors were understandably happy this past week when Bristol Myers Squibb (BMS) agreed to acquire its partner in developing the blockbuster multiple myeloma drug Abecma ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling itself to partner Bristol Myers Squibb. Bristol Myers has agreed to buy out ...

Bristol Myers Squibb is acquiring 2seventy bio, a deal that gives the pharmaceutical giant full control over the partnered cancer cell therapy Abecma as that product faces headwinds in a ...

He noted that the company's focus on Abecma has positioned them to potentially reach quarterly breakeven by the end of 2025. The company's financial position includes approximately $184 million in ...

They co-developed Abecma (idecabtagene vicleucel), a BCMA-targeted chimeric antigen receptor (CAR)-T cell therapy for multiple myeloma, which secured US Food and Drug Administration (FDA ...

(Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Bristol Myers Squibb (BMS). Further details on fourth quarter and ...

“A year ago, 2seventy decided to exclusively focus on unlocking the value of Abecma, with the goal of delivering more time for people living with multiple myeloma and maximizing value for all ...